Listen
COPAXONE
-
Opinions on drugs -
Posted on
Apr 06 2011
- Updated on
May 21 2011
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication "patients who have experienced a well-defined first clinical episode and are determined to be at high risk of developing clinically definite multiple sclerosis".
-
Clinical Benefit
| Substantial |
The actual benefit of COPAXONE is substantial. |
Clinical Added Value
| no clinical added value |
COPAXONE does not provide any improvement in actual benefit (IAB V) in the treatment of patients who have experienced a single clinical episode and who are considered to be at high risk of developing clinically definite multiple sclerosis. |
English version
Contact Us
Évaluation des médicaments
